Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure

Three major cardiovascular outcome trials (CVOTs) with a new class of antidiabetic drugs - sodium-glucose cotransporter 2 (SGLT2) inhibitors (EMPA-REG OUTCOME trial with empagliflozin, CANVAS Program with canagliflozin, DECLARE-TIMI 58 with dapagliflozin) unexpectedly showed that cardiovascular outc...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:World J Diabetes
Main Authors: Grubić Rotkvić, Petra, Cigrovski Berković, Maja, Bulj, Nikola, Rotkvić, Luka, Ćelap, Ivana
Format: Artigo
Jezik:Inglês
Izdano: Baishideng Publishing Group Inc 2020
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7415232/
https://ncbi.nlm.nih.gov/pubmed/32843930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4239/wjd.v11.i7.269
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki